IDBS Blog | 9th August 2011

Industry Pressures Driving Collaboration for Translational Medicine

Funding cuts for academia and continuing issues for the pharmaceutical industry are causing considerable stress in life sciences and healthcare research. However, new opportunities are developing to enable industry to access high quality, longitudinal patient and genetic data for collaborative translational medicine studies. So does that mean an end to ‘going it alone’?

In my view – yes.

For pharma and academia, collaboration in translational science shouldn’t be feared. It’s already leading to valuable industry funded partnerships between these groups that will ensure vital clinical trials/translational studies continue to lead to improved disease understanding and treatment. And that means better outcomes for everyone.

Not convinced? Read a full discussion in August’s edition of International Clinical Trials.

About IDBSContact us

More news

IDBS Joins BioPhorum

IDBS, a leading R&D technology and solutions provider and Tableau, the world’s leading analytics platform, announced a strategic partnership to integrate Tableau into the IDBS suite of products. The collaboration will be based on embedding Tableau’s visual and analytics capabilities into the IDBS product offerings.

Read more

i3 2021 On Demand

i3 our premier annual customer event where we bring together science, IT and R&D business leaders to share ideas, create new insights and advance innovation and this year we went virtual. During i3 you will gain insights from your peers…

Read more